Insider Watch Reporter: Rod Lippincott an Insider in Heska Corp (NASDAQ:HSKA) Unloaded 5,000 Shares

November 23, 2016 - By Linda Rogers

Insider Watch Reporter: Rod Lippincott an Insider in Heska Corp (NASDAQ:HSKA) Unloaded 5,000 Shares

Rod Lippincott Insider Sell

The EVP – Comp. Animal Health Sales of Heska Corp, Rod Lippincott, has just sold – 5,000 shares of the corporation he’s leading – coming to a total trade of $324,258 USD (this based on share price of $64.9). Presently, Rod Lippincott owns 8,192 shares which are equivalent to around 0.12% of the company’s total market cap. The dated November 22, 2016 transaction’s document which was filed with the (SEC) is accessible online here.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. As per Thursday, August 4, the company rating was downgraded by Gabelli. As per Friday, April 1, the company rating was initiated by CL King. The company was upgraded on Tuesday, August 25 by TheStreet.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio dropped, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Moreover, Fuller & Thaler Asset has 0% invested in Heska Corp (NASDAQ:HSKA) for 1,500 shares. Nationwide Fund Advsrs has 0% invested in the company for 3,833 shares. Raymond James Trust Na accumulated 13,000 shares or 0.04% of the stock. Parametric Associates last reported 14,909 shares in the company. Metropolitan Life Insur last reported 4,853 shares in the company. Vanguard holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 226,843 shares. Driehaus Capital Management Ltd Llc last reported 0.08% of its portfolio in the stock. Moreover, Rhumbline Advisers has 0% invested in Heska Corp (NASDAQ:HSKA) for 5,966 shares. Wedge Capital Management L Limited Partnership Nc last reported 0% of its portfolio in the stock. Barclays Public has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA). Panagora Asset holds 0.02% or 83,884 shares in its portfolio. Oxford Asset Mgmt reported 60,215 shares or 0.09% of all its holdings. Eam Ltd Liability holds 0.37% or 65,913 shares in its portfolio. Pdt Prtn Ltd Limited Liability Company has invested 0.03% of its portfolio in Heska Corp (NASDAQ:HSKA). Wells Fargo Com Mn reported 2,828 shares or 0% of all its holdings.

Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 14 insider sales for $6.35 million net activity. $879 worth of shares were sold by Wilson Kevin S. on Friday, July 29. Shares for $262,642 were sold by NAPOLITANO JASON A on Thursday, September 1. 5,000 shares were sold by Asakowicz Steve, worth $305,000. On Monday, November 7 McGinley Michael J sold $601,051 worth of the stock or 9,998 shares. 137 Heska Corp (NASDAQ:HSKA) shares with value of $7,028 were sold by McMahon John.

About 18,705 shares traded hands. Heska Corp (NASDAQ:HSKA) has risen 129.45% since April 21, 2016 and is uptrending. It has outperformed by 124.12% the S&P500.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $428.19 million. The Firm focuses on the canine and feline companion animal health markets. It has a 53.22 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 EPS, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.40 million for 44.68 P/E if the $0.37 EPS becomes a reality. After $0.45 actual EPS reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

More news for Heska Corp (NASDAQ:HSKA) were recently published by: Marketwatch.com, which released: “Heska downgraded to neutral from buy at B. Riley” on December 21, 2009. Quotes.Wsj.com‘s article titled: “News Heska Corp.HSKA” and published on February 12, 2011 is yet another important article.

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>